FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2801082038> ?p ?o ?g. }

• W2801082038 endingPage "23002" @default.
• W2801082038 startingPage "22986" @default.
• W2801082038 abstract "// Takaaki Oba 1 and Ken-Ichi Ito 1 1 Division of Breast, Endocrine and Respiratory Surgery, Department of Surgery II, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, Japan Correspondence to: Ken-Ichi Ito, email: kenito@shinshu-u.ac.jp Keywords: eribulin; paclitaxel; triple-negative breast cancer; epithelial-mesenchymal transition; mesenchymal-epithelial transition Received: December 26, 2017      Accepted: April 05, 2018      Published: May 01, 2018 ABSTRACT Improved prognosis for triple-negative breast cancer (TNBC) has currently plateaued and the development of novel therapeutic strategies is required. Therefore, we aimed to explore the anti-tumor effect of eribulin and paclitaxel combination therapy for TNBC. The effect of eribulin and paclitaxel in combination was tested, with both concurrent and sequential administration, using four TNBC cell lines (MDA-MB-231, Hs578T, MDA-MB-157, and Mx-1) in vitro and in an MDA-MB-231 BALB/c-nu/nu mouse xenograft model. The expression of epithelial-mesenchymal phenotypic markers was analyzed by western blotting and immunohistochemical analyses. Simultaneous administration of eribulin and paclitaxel resulted in a synergistic anti-tumor effect with MDA-MB-231 and Hs578T cells, but not MDA-MB-157 and Mx-1 cells, in vitro . Moreover, pre-treatment with one drug significantly enhanced sensitivity to the subsequently administrated second drug in MDA-MB-231 and Hs578T cells. Eribulin increased E-cadherin expression and decreased the expression of mesenchymal markers in MDA-MB-231 and Hs578T cells. In contrast, paclitaxel increased the expression of mesenchymal markers. When epithelial-mesenchymal transition was induced by TGF-β1, eribulin sensitivity was enhanced. In contrast, a TGF-β receptor kinase inhibitor decreased eribulin sensitivity. In MDA-MB-231 tumor-bearing mice, concurrent administration of low doses of eribulin and paclitaxel significantly inhibited tumor growth compared to that with either monotherapy. Moreover, single administration of eribulin before the initiation of paclitaxel treatment decreased vimentin expression and reduced the average tumor volume in a mouse xenograft model. Eribulin and paclitaxel show synergistic anti-tumor effect by altering the epithelial-mesenchymal phenotype. This combination therapy could represent a novel therapeutic strategy for TNBC." @default.
• W2801082038 created "2018-05-17" @default.
• W2801082038 creator A5049076885 @default.
• W2801082038 creator A5086349111 @default.
• W2801082038 date "2018-05-01" @default.
• W2801082038 modified "2023-10-14" @default.
• W2801082038 title "Combination of two anti-tubulin agents, eribulin and paclitaxel, enhances anti-tumor effects on triple-negative breast cancer through mesenchymal-epithelial transition" @default.
• W2801082038 cites W1555009525 @default.
• W2801082038 cites W1665925013 @default.
• W2801082038 cites W186854340 @default.
• W2801082038 cites W1971270230 @default.
• W2801082038 cites W1977075884 @default.
• W2801082038 cites W1983225377 @default.
• W2801082038 cites W1998236197 @default.
• W2801082038 cites W1999132074 @default.
• W2801082038 cites W2005895632 @default.
• W2801082038 cites W2025647419 @default.
• W2801082038 cites W2028144293 @default.
• W2801082038 cites W2028593825 @default.
• W2801082038 cites W2033732670 @default.
• W2801082038 cites W2042198997 @default.
• W2801082038 cites W2044066240 @default.
• W2801082038 cites W2061860268 @default.
• W2801082038 cites W2063011414 @default.
• W2801082038 cites W2074446011 @default.
• W2801082038 cites W2082326948 @default.
• W2801082038 cites W2091729045 @default.
• W2801082038 cites W2096027508 @default.
• W2801082038 cites W2097642044 @default.
• W2801082038 cites W2098455835 @default.
• W2801082038 cites W2100751052 @default.
• W2801082038 cites W2114639059 @default.
• W2801082038 cites W2123027432 @default.
• W2801082038 cites W2123851255 @default.
• W2801082038 cites W2127152525 @default.
• W2801082038 cites W2127564111 @default.
• W2801082038 cites W2131670056 @default.
• W2801082038 cites W2134539328 @default.
• W2801082038 cites W2137530154 @default.
• W2801082038 cites W2138941973 @default.
• W2801082038 cites W2142807621 @default.
• W2801082038 cites W2145063352 @default.
• W2801082038 cites W2149162265 @default.
• W2801082038 cites W2157576385 @default.
• W2801082038 cites W2170602872 @default.
• W2801082038 cites W2297248108 @default.
• W2801082038 cites W2345876088 @default.
• W2801082038 cites W2515702573 @default.
• W2801082038 cites W2537234361 @default.
• W2801082038 cites W2739191486 @default.
• W2801082038 doi "https://doi.org/10.18632/oncotarget.25184" @default.
• W2801082038 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5955406" @default.
• W2801082038 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29796167" @default.
• W2801082038 hasPublicationYear "2018" @default.
• W2801082038 type Work @default.
• W2801082038 sameAs 2801082038 @default.
• W2801082038 citedByCount "12" @default.
• W2801082038 countsByYear W28010820382019 @default.
• W2801082038 countsByYear W28010820382020 @default.
• W2801082038 countsByYear W28010820382021 @default.
• W2801082038 countsByYear W28010820382022 @default.
• W2801082038 countsByYear W28010820382023 @default.
• W2801082038 crossrefType "journal-article" @default.
• W2801082038 hasAuthorship W2801082038A5049076885 @default.
• W2801082038 hasAuthorship W2801082038A5086349111 @default.
• W2801082038 hasBestOaLocation W28010820381 @default.
• W2801082038 hasConcept C121608353 @default.
• W2801082038 hasConcept C126322002 @default.
• W2801082038 hasConcept C142724271 @default.
• W2801082038 hasConcept C198826908 @default.
• W2801082038 hasConcept C2775930923 @default.
• W2801082038 hasConcept C2776387010 @default.
• W2801082038 hasConcept C2777292972 @default.
• W2801082038 hasConcept C2779013556 @default.
• W2801082038 hasConcept C2780110267 @default.
• W2801082038 hasConcept C502942594 @default.
• W2801082038 hasConcept C530470458 @default.
• W2801082038 hasConcept C71924100 @default.
• W2801082038 hasConcept C76419328 @default.
• W2801082038 hasConceptScore W2801082038C121608353 @default.
• W2801082038 hasConceptScore W2801082038C126322002 @default.
• W2801082038 hasConceptScore W2801082038C142724271 @default.
• W2801082038 hasConceptScore W2801082038C198826908 @default.
• W2801082038 hasConceptScore W2801082038C2775930923 @default.
• W2801082038 hasConceptScore W2801082038C2776387010 @default.
• W2801082038 hasConceptScore W2801082038C2777292972 @default.
• W2801082038 hasConceptScore W2801082038C2779013556 @default.
• W2801082038 hasConceptScore W2801082038C2780110267 @default.
• W2801082038 hasConceptScore W2801082038C502942594 @default.
• W2801082038 hasConceptScore W2801082038C530470458 @default.
• W2801082038 hasConceptScore W2801082038C71924100 @default.
• W2801082038 hasConceptScore W2801082038C76419328 @default.
• W2801082038 hasIssue "33" @default.
• W2801082038 hasLocation W28010820381 @default.
• W2801082038 hasLocation W28010820382 @default.
• W2801082038 hasLocation W28010820383 @default.
• W2801082038 hasLocation W28010820384 @default.
• W2801082038 hasOpenAccess W2801082038 @default.

• next